TY - JOUR
T1 - Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
AU - Takamatsu, Kimiharu
AU - Tanaka, Nobuyuki
AU - Hakozaki, Kyohei
AU - Takahashi, Ryohei
AU - Teranishi, Yu
AU - Murakami, Tetsushi
AU - Kufukihara, Ryohei
AU - Niwa, Naoya
AU - Mikami, Shuji
AU - Shinojima, Toshiaki
AU - Sasaki, Takashi
AU - Sato, Yusuke
AU - Kume, Haruki
AU - Ogawa, Seishi
AU - Kakimi, Kazuhiro
AU - Kamatani, Takashi
AU - Miya, Fuyuki
AU - Tsunoda, Tatsuhiko
AU - Aimono, Eriko
AU - Nishihara, Hiroshi
AU - Sawada, Kazuaki
AU - Imamura, Takeshi
AU - Mizuno, Ryuichi
AU - Oya, Mototsugu
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - A cutting edge therapy for future immuno-oncology is targeting a new series of inhibitory receptors (IRs): LAG-3, TIM-3, and TIGIT. Both immunogenomic analyses and diagnostic platforms to distinguish candidates and predict good responders to these IR-related agents are vital in clinical pathology. By applying an automated single-cell count for immunolabelled LAG-3, TIM-3, and TIGIT, we reveal that individual IR levels with exclusive domination in each tumour can serve as valid biomarkers for profiling human renal cell carcinoma (RCC). We uncover the immunogenomic landscape associated with individual IR levels in human RCC tumours with metastases in various organs and histological subtypes. We then externally validate our results and devise a workflow with optimal biomarker cut-offs for discriminating the LAG-3, TIM-3, and TIGIT tumour profiles. The discrimination of LAG-3, TIM-3, and TIGIT profiles in tumours may have a broad impact on investigations of immunotherapy responses after targeting a new series of IRs.
AB - A cutting edge therapy for future immuno-oncology is targeting a new series of inhibitory receptors (IRs): LAG-3, TIM-3, and TIGIT. Both immunogenomic analyses and diagnostic platforms to distinguish candidates and predict good responders to these IR-related agents are vital in clinical pathology. By applying an automated single-cell count for immunolabelled LAG-3, TIM-3, and TIGIT, we reveal that individual IR levels with exclusive domination in each tumour can serve as valid biomarkers for profiling human renal cell carcinoma (RCC). We uncover the immunogenomic landscape associated with individual IR levels in human RCC tumours with metastases in various organs and histological subtypes. We then externally validate our results and devise a workflow with optimal biomarker cut-offs for discriminating the LAG-3, TIM-3, and TIGIT tumour profiles. The discrimination of LAG-3, TIM-3, and TIGIT profiles in tumours may have a broad impact on investigations of immunotherapy responses after targeting a new series of IRs.
UR - http://www.scopus.com/inward/record.url?scp=85115379440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115379440&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-25865-0
DO - 10.1038/s41467-021-25865-0
M3 - Article
C2 - 34545095
AN - SCOPUS:85115379440
SN - 2041-1723
VL - 12
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 5547
ER -